Neurodegenerative Diseases Clinical Trial
Official title:
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
This is a proof-of-concept phase 2 clinical trial to investigate the long-term safety and efficacy of Allo to function as a regenerative therapeutic to restore structural integrity and cognitive function of the brain in participants with mild Alzheimer's disease (AD) dementia. Study participants will be male and female, APOE ε4 positive diagnosed with probable AD, Mini-Mental State Exam (MMSE) 20 to 26, ages 55 to 80 years old. After a 2-4-week screening period, participants will be randomized to 4 mg Allo (administered intravenously over 30 minutes, once per week, in clinic) or matching placebo, 1:1 allocation, for a period of 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase). Brain imaging to evaluate the primary endpoint will be conducted at baseline, 6 and 12 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
| Completed |
NCT05788133 -
The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.
|
N/A | |
| Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
| Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04265482 -
Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
|
||
| Not yet recruiting |
NCT02222779 -
Quantification of Transition Metals
|
N/A | |
| Recruiting |
NCT01291550 -
Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
|
N/A | |
| Completed |
NCT01450891 -
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
|
N/A | |
| Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
| Recruiting |
NCT06148233 -
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
|
N/A | |
| Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
| Completed |
NCT06251830 -
Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
|
||
| Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
| Completed |
NCT03353207 -
Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
|
||
| Completed |
NCT05095870 -
Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
|
||
| Recruiting |
NCT05784090 -
Correlation Between Melatonin Levels in Different Biological Fluids
|
||
| Completed |
NCT02108769 -
Yogic Breathing Changes Salivary Components
|
N/A | |
| Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
| Recruiting |
NCT05235802 -
Long-term Follow-up in Severe Traumatic Brain Injury
|
||
| Recruiting |
NCT04820881 -
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
|